[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2002-05, Vol.136 (2), p.303-311 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 311 |
|---|---|
| container_issue | 2 |
| container_start_page | 303 |
| container_title | British journal of pharmacology |
| container_volume | 136 |
| creator | Calo, Girolamo Rizzi, Anna Rizzi, Daniela Bigoni, Raffaella Guerrini, Remo Marzola, Giuliano Marti, Matteo McDonald, John Morari, Michele Lambert, David G Salvadori, Severo Regoli, Domenico |
| description | Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor ligand, [Nphe1,Arg14,Lys15]N/OFQ‐NH2 (UFP‐101).
UFP‐101 binds to the human recombinant NOP receptor expressed in Chinese hamster ovary (CHO) cells with high affinity (pKi 10.2) and shows more than 3000 fold selectivity over classical opioid receptors. UFP‐101 competitively antagonizes the effects of N/OFQ on GTPγ35S binding in CHOhNOP cell membranes (pA2 9.1) and on cyclic AMP accumulation in CHOhNOP cells (pA2 7.1), being per se inactive at concentrations up to 10 μM.
In isolated peripheral tissues of mice, rats and guinea‐pigs, and in rat cerebral cortex synaptosomes preloaded with [3H]‐5‐HT, UFP‐101 competitively antagonized the effects of N/OFQ with pA2 values in the range of 7.3–7.7. In the same preparations, the peptide was inactive alone and did not modify the effects of classical opioid receptor agonists.
UFP‐101 is also active in vivo where it prevented the depressant action on locomotor activity and the pronociceptive effect induced by 1 nmol N/OFQ i.c.v. in the mouse. In the tail withdrawal assay, UFP‐101 at 10 nmol produces per se a robust and long lasting antinociceptive effect.
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
British Journal of Pharmacology (2002) 136, 303–311; doi:10.1038/sj.bjp.0704706 |
| doi_str_mv | 10.1038/sj.bjp.0704706 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1573345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71684440</sourcerecordid><originalsourceid>FETCH-LOGICAL-j4019-b1a00e1dfc4c708f90f0b1be2142fd5e3e8448a4cd8eecc316a27461c5b346343</originalsourceid><addsrcrecordid>eNpdkkGP0zAQhSMEYsvClSOKkODUdGdiJ3YvKy0rliJVBSQ4IWQ5zqR1lNohTot64yfwG_kleNkuC5xGnvfp6Y38kuQpwgyBybPQzqq2n4EALqC8l0yQizIrmMT7yQQARIYo5UnyKIQWIIqieJicYA4IQsIkCZ9X_YZwejGskU-Xh4DFl5U31lA_Wvfz-4_VIp-mOnV-T13a-5HcmGpXp4E6MqPdU3yNeu2dDWPqm3TcUIRvDc780G-0sy69-pAOdL30w-PkQaO7QE-O8zT5dPX64-UiW7578_byYpm1HHCeVagBCOvGcCNANnNooMKKcuR5UxfESHIuNTe1JDKGYalzwUs0RcV4yTg7Tc5vfPtdtaXaxOiD7lQ_2K0eDsprq_5VnN2otd8rLARjvIgGL48Gg_-6ozCqrQ2Guk478rugBJYxAocIPv8PbP1ucPE4laNAIYQUEXr2d5w_OW4_IwIvjoAORnfNoJ2x4Y5jYs7Zb47dcN9sR4c7HdR1JVRoVayEOlZCvXq_4OV8zn4BvKqq9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217177787</pqid></control><display><type>article</type><title>[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor</title><source>PubMed (Medline)</source><source>MEDLINE</source><source>Wiley Online Library</source><source>Wiley Free Archive</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Calo, Girolamo ; Rizzi, Anna ; Rizzi, Daniela ; Bigoni, Raffaella ; Guerrini, Remo ; Marzola, Giuliano ; Marti, Matteo ; McDonald, John ; Morari, Michele ; Lambert, David G ; Salvadori, Severo ; Regoli, Domenico</creator><creatorcontrib>Calo, Girolamo ; Rizzi, Anna ; Rizzi, Daniela ; Bigoni, Raffaella ; Guerrini, Remo ; Marzola, Giuliano ; Marti, Matteo ; McDonald, John ; Morari, Michele ; Lambert, David G ; Salvadori, Severo ; Regoli, Domenico</creatorcontrib><description>Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor ligand, [Nphe1,Arg14,Lys15]N/OFQ‐NH2 (UFP‐101).
UFP‐101 binds to the human recombinant NOP receptor expressed in Chinese hamster ovary (CHO) cells with high affinity (pKi 10.2) and shows more than 3000 fold selectivity over classical opioid receptors. UFP‐101 competitively antagonizes the effects of N/OFQ on GTPγ35S binding in CHOhNOP cell membranes (pA2 9.1) and on cyclic AMP accumulation in CHOhNOP cells (pA2 7.1), being per se inactive at concentrations up to 10 μM.
In isolated peripheral tissues of mice, rats and guinea‐pigs, and in rat cerebral cortex synaptosomes preloaded with [3H]‐5‐HT, UFP‐101 competitively antagonized the effects of N/OFQ with pA2 values in the range of 7.3–7.7. In the same preparations, the peptide was inactive alone and did not modify the effects of classical opioid receptor agonists.
UFP‐101 is also active in vivo where it prevented the depressant action on locomotor activity and the pronociceptive effect induced by 1 nmol N/OFQ i.c.v. in the mouse. In the tail withdrawal assay, UFP‐101 at 10 nmol produces per se a robust and long lasting antinociceptive effect.
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
British Journal of Pharmacology (2002) 136, 303–311; doi:10.1038/sj.bjp.0704706</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1038/sj.bjp.0704706</identifier><identifier>PMID: 12010780</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Biological and medical sciences ; Cell receptors ; Cell structures and functions ; CHO Cells ; Cricetinae ; Dose-Response Relationship, Drug ; Fundamental and applied biological sciences. Psychology ; Guinea Pigs ; In Vitro Techniques ; isolated tissues ; locomotor activity, mice ; Male ; Medical sciences ; Mice ; Molecular and cellular biology ; Motor Activity - drug effects ; Motor Activity - physiology ; Narcotic Antagonists ; native and recombinant receptors ; Neuropeptide receptors ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Nociceptin/orphanin FQ ; NOP receptors ; Opioid Peptides - chemistry ; Opioid Peptides - metabolism ; Opioid Peptides - pharmacology ; Pain Measurement - drug effects ; Peptide Fragments - chemistry ; Peptide Fragments - metabolism ; Peptide Fragments - pharmacology ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Rabbits ; rat cerebral cortex synaptosomes ; Rats ; Rats, Sprague-Dawley ; receptor antagonist ; Receptors, Opioid - metabolism ; tail withdrawal assay ; UFP‐101</subject><ispartof>British journal of pharmacology, 2002-05, Vol.136 (2), p.303-311</ispartof><rights>2002 British Pharmacological Society</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Nature Publishing Group May 2002</rights><rights>Copyright 2002, Nature Publishing Group 2002 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573345/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573345/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,1412,1428,27905,27906,45555,45556,46390,46814,53772,53774</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13794380$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12010780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calo, Girolamo</creatorcontrib><creatorcontrib>Rizzi, Anna</creatorcontrib><creatorcontrib>Rizzi, Daniela</creatorcontrib><creatorcontrib>Bigoni, Raffaella</creatorcontrib><creatorcontrib>Guerrini, Remo</creatorcontrib><creatorcontrib>Marzola, Giuliano</creatorcontrib><creatorcontrib>Marti, Matteo</creatorcontrib><creatorcontrib>McDonald, John</creatorcontrib><creatorcontrib>Morari, Michele</creatorcontrib><creatorcontrib>Lambert, David G</creatorcontrib><creatorcontrib>Salvadori, Severo</creatorcontrib><creatorcontrib>Regoli, Domenico</creatorcontrib><title>[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor ligand, [Nphe1,Arg14,Lys15]N/OFQ‐NH2 (UFP‐101).
UFP‐101 binds to the human recombinant NOP receptor expressed in Chinese hamster ovary (CHO) cells with high affinity (pKi 10.2) and shows more than 3000 fold selectivity over classical opioid receptors. UFP‐101 competitively antagonizes the effects of N/OFQ on GTPγ35S binding in CHOhNOP cell membranes (pA2 9.1) and on cyclic AMP accumulation in CHOhNOP cells (pA2 7.1), being per se inactive at concentrations up to 10 μM.
In isolated peripheral tissues of mice, rats and guinea‐pigs, and in rat cerebral cortex synaptosomes preloaded with [3H]‐5‐HT, UFP‐101 competitively antagonized the effects of N/OFQ with pA2 values in the range of 7.3–7.7. In the same preparations, the peptide was inactive alone and did not modify the effects of classical opioid receptor agonists.
UFP‐101 is also active in vivo where it prevented the depressant action on locomotor activity and the pronociceptive effect induced by 1 nmol N/OFQ i.c.v. in the mouse. In the tail withdrawal assay, UFP‐101 at 10 nmol produces per se a robust and long lasting antinociceptive effect.
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
British Journal of Pharmacology (2002) 136, 303–311; doi:10.1038/sj.bjp.0704706</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell receptors</subject><subject>Cell structures and functions</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Guinea Pigs</subject><subject>In Vitro Techniques</subject><subject>isolated tissues</subject><subject>locomotor activity, mice</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Molecular and cellular biology</subject><subject>Motor Activity - drug effects</subject><subject>Motor Activity - physiology</subject><subject>Narcotic Antagonists</subject><subject>native and recombinant receptors</subject><subject>Neuropeptide receptors</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nociceptin/orphanin FQ</subject><subject>NOP receptors</subject><subject>Opioid Peptides - chemistry</subject><subject>Opioid Peptides - metabolism</subject><subject>Opioid Peptides - pharmacology</subject><subject>Pain Measurement - drug effects</subject><subject>Peptide Fragments - chemistry</subject><subject>Peptide Fragments - metabolism</subject><subject>Peptide Fragments - pharmacology</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Rabbits</subject><subject>rat cerebral cortex synaptosomes</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>receptor antagonist</subject><subject>Receptors, Opioid - metabolism</subject><subject>tail withdrawal assay</subject><subject>UFP‐101</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkkGP0zAQhSMEYsvClSOKkODUdGdiJ3YvKy0rliJVBSQ4IWQ5zqR1lNohTot64yfwG_kleNkuC5xGnvfp6Y38kuQpwgyBybPQzqq2n4EALqC8l0yQizIrmMT7yQQARIYo5UnyKIQWIIqieJicYA4IQsIkCZ9X_YZwejGskU-Xh4DFl5U31lA_Wvfz-4_VIp-mOnV-T13a-5HcmGpXp4E6MqPdU3yNeu2dDWPqm3TcUIRvDc780G-0sy69-pAOdL30w-PkQaO7QE-O8zT5dPX64-UiW7578_byYpm1HHCeVagBCOvGcCNANnNooMKKcuR5UxfESHIuNTe1JDKGYalzwUs0RcV4yTg7Tc5vfPtdtaXaxOiD7lQ_2K0eDsprq_5VnN2otd8rLARjvIgGL48Gg_-6ozCqrQ2Guk478rugBJYxAocIPv8PbP1ucPE4laNAIYQUEXr2d5w_OW4_IwIvjoAORnfNoJ2x4Y5jYs7Zb47dcN9sR4c7HdR1JVRoVayEOlZCvXq_4OV8zn4BvKqq9w</recordid><startdate>200205</startdate><enddate>200205</enddate><creator>Calo, Girolamo</creator><creator>Rizzi, Anna</creator><creator>Rizzi, Daniela</creator><creator>Bigoni, Raffaella</creator><creator>Guerrini, Remo</creator><creator>Marzola, Giuliano</creator><creator>Marti, Matteo</creator><creator>McDonald, John</creator><creator>Morari, Michele</creator><creator>Lambert, David G</creator><creator>Salvadori, Severo</creator><creator>Regoli, Domenico</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200205</creationdate><title>[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor</title><author>Calo, Girolamo ; Rizzi, Anna ; Rizzi, Daniela ; Bigoni, Raffaella ; Guerrini, Remo ; Marzola, Giuliano ; Marti, Matteo ; McDonald, John ; Morari, Michele ; Lambert, David G ; Salvadori, Severo ; Regoli, Domenico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j4019-b1a00e1dfc4c708f90f0b1be2142fd5e3e8448a4cd8eecc316a27461c5b346343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell receptors</topic><topic>Cell structures and functions</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Guinea Pigs</topic><topic>In Vitro Techniques</topic><topic>isolated tissues</topic><topic>locomotor activity, mice</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Molecular and cellular biology</topic><topic>Motor Activity - drug effects</topic><topic>Motor Activity - physiology</topic><topic>Narcotic Antagonists</topic><topic>native and recombinant receptors</topic><topic>Neuropeptide receptors</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nociceptin/orphanin FQ</topic><topic>NOP receptors</topic><topic>Opioid Peptides - chemistry</topic><topic>Opioid Peptides - metabolism</topic><topic>Opioid Peptides - pharmacology</topic><topic>Pain Measurement - drug effects</topic><topic>Peptide Fragments - chemistry</topic><topic>Peptide Fragments - metabolism</topic><topic>Peptide Fragments - pharmacology</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Rabbits</topic><topic>rat cerebral cortex synaptosomes</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>receptor antagonist</topic><topic>Receptors, Opioid - metabolism</topic><topic>tail withdrawal assay</topic><topic>UFP‐101</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calo, Girolamo</creatorcontrib><creatorcontrib>Rizzi, Anna</creatorcontrib><creatorcontrib>Rizzi, Daniela</creatorcontrib><creatorcontrib>Bigoni, Raffaella</creatorcontrib><creatorcontrib>Guerrini, Remo</creatorcontrib><creatorcontrib>Marzola, Giuliano</creatorcontrib><creatorcontrib>Marti, Matteo</creatorcontrib><creatorcontrib>McDonald, John</creatorcontrib><creatorcontrib>Morari, Michele</creatorcontrib><creatorcontrib>Lambert, David G</creatorcontrib><creatorcontrib>Salvadori, Severo</creatorcontrib><creatorcontrib>Regoli, Domenico</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calo, Girolamo</au><au>Rizzi, Anna</au><au>Rizzi, Daniela</au><au>Bigoni, Raffaella</au><au>Guerrini, Remo</au><au>Marzola, Giuliano</au><au>Marti, Matteo</au><au>McDonald, John</au><au>Morari, Michele</au><au>Lambert, David G</au><au>Salvadori, Severo</au><au>Regoli, Domenico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2002-05</date><risdate>2002</risdate><volume>136</volume><issue>2</issue><spage>303</spage><epage>311</epage><pages>303-311</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>Nociceptin/orphanin FQ (N/OFQ) modulates several biological functions by activating a specific G‐protein coupled receptor (NOP). Few molecules are available that selectively activate or block the NOP receptor. Here we describe the in vitro and in vivo pharmacological profile of a novel NOP receptor ligand, [Nphe1,Arg14,Lys15]N/OFQ‐NH2 (UFP‐101).
UFP‐101 binds to the human recombinant NOP receptor expressed in Chinese hamster ovary (CHO) cells with high affinity (pKi 10.2) and shows more than 3000 fold selectivity over classical opioid receptors. UFP‐101 competitively antagonizes the effects of N/OFQ on GTPγ35S binding in CHOhNOP cell membranes (pA2 9.1) and on cyclic AMP accumulation in CHOhNOP cells (pA2 7.1), being per se inactive at concentrations up to 10 μM.
In isolated peripheral tissues of mice, rats and guinea‐pigs, and in rat cerebral cortex synaptosomes preloaded with [3H]‐5‐HT, UFP‐101 competitively antagonized the effects of N/OFQ with pA2 values in the range of 7.3–7.7. In the same preparations, the peptide was inactive alone and did not modify the effects of classical opioid receptor agonists.
UFP‐101 is also active in vivo where it prevented the depressant action on locomotor activity and the pronociceptive effect induced by 1 nmol N/OFQ i.c.v. in the mouse. In the tail withdrawal assay, UFP‐101 at 10 nmol produces per se a robust and long lasting antinociceptive effect.
UFP‐101 is a novel, potent and selective NOP receptor antagonist which appears to be a useful tool for future investigations of the N/OFQ‐NOP receptor system.
British Journal of Pharmacology (2002) 136, 303–311; doi:10.1038/sj.bjp.0704706</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12010780</pmid><doi>10.1038/sj.bjp.0704706</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2002-05, Vol.136 (2), p.303-311 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1573345 |
| source | PubMed (Medline); MEDLINE; Wiley Online Library; Wiley Free Archive; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Animals Biological and medical sciences Cell receptors Cell structures and functions CHO Cells Cricetinae Dose-Response Relationship, Drug Fundamental and applied biological sciences. Psychology Guinea Pigs In Vitro Techniques isolated tissues locomotor activity, mice Male Medical sciences Mice Molecular and cellular biology Motor Activity - drug effects Motor Activity - physiology Narcotic Antagonists native and recombinant receptors Neuropeptide receptors Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Nociceptin/orphanin FQ NOP receptors Opioid Peptides - chemistry Opioid Peptides - metabolism Opioid Peptides - pharmacology Pain Measurement - drug effects Peptide Fragments - chemistry Peptide Fragments - metabolism Peptide Fragments - pharmacology Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems Pharmacology. Drug treatments Rabbits rat cerebral cortex synaptosomes Rats Rats, Sprague-Dawley receptor antagonist Receptors, Opioid - metabolism tail withdrawal assay UFP‐101 |
| title | [Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5BNphe1,Arg14,Lys15%5DNociceptin%E2%80%90NH2,%20a%20novel%20potent%20and%20selective%20antagonist%20of%20the%20nociceptin/orphanin%20FQ%20receptor&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Calo,%20Girolamo&rft.date=2002-05&rft.volume=136&rft.issue=2&rft.spage=303&rft.epage=311&rft.pages=303-311&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1038/sj.bjp.0704706&rft_dat=%3Cproquest_pubme%3E71684440%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217177787&rft_id=info:pmid/12010780&rfr_iscdi=true |